FDA已发警告信(FDA警告信:华润紫竹药业有限公司)
Zhejiang Huahai Pharmaceutical Nov 2016
浙江华海药业有限公司
检查员:Peter Baker FDA, Justin Boyd
•Inspection end: 18 Nov 2016
检查结束日期:2016-11-18
•Location: Taizhou, China
位置:中国台州
检查缺陷:
During set-up and intervention using the RABS operator were observed to use the XX directly above sterile surface and components.
使用RABS进行装机和干扰期间,观察到操作人员在无菌表面和组件上直接使用XX。
Jiangsu Hengrui Medicine
江苏恒瑞药业有限公司
检查员:Peter Baker, Christopher Middendorf
•Inspection end: 02 Nov 2016
检查结束日期:2016-11-02
•Location: Lianyungang, China
位置:中国连云港
检查缺陷:
Quality system
质量体系
Deviation regarding GMP products or process are not always handled within the quality system. Specifically, your firm failed to investigate deviation to good laboratory data integrity practices within the quality system.
质量体系未能处理GMP产品或工艺相关的偏差。尤其是,贵公司未能调查违背良好实验室数据完整性规范的偏差。
Zhejiang Jiuzhou Pharmaceutical
浙江九洲药业有限公司
检查员:Peter Baker FDA, Christopher Middendorf
•Inspection end: 23 Jan 2016
检查结束日期:2016-01-23
•Location: Taizhou, China
位置:中国台州
检查缺陷:
Facilites and equipment system:
设备设施系统
maintenance activities are not recorded in XX equipment use logs as required by your SOP SMP-CH-01
未按照SOP SMP-CH-01要求在XX设备使用日志中记录维护活动